Search - tctmd.com

Displaying 1 - 20 of 88

Sort: Relevancy | Date

News Daily News

As More Peripheral Interventions Go Radial, the AHA Offers Some Insights

L.A. McKeown

December 12, 2024

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

L.A. McKeown

May 10, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Todd Neale

October 16, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

Presentation ESC 2022

Impact on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: a meta-analysis of individual patient data from seven multicenter randomized clinical trials

Presenter: Giuseppe Gargiulo

August 29, 2022

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Daily News

MOSAIC: Home Intervention Boosts Walking Time in PAD Patients

L.A. McKeown

April 15, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Daily News

PAD Continues to Elude Clinicians, Despite Gains: AHA

L.A. McKeown

August 05, 2021

The finding, from a study with a mean follow-up of 2-and-a-half years, bolsters support for trials and device use to continue.

News Daily News

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

L.A. McKeown

December 18, 2020

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Conference News LINC 2020

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

L.A. McKeown

January 31, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Conference News VIVA 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

L.A. McKeown

November 13, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Todd Neale

August 07, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

Shelley Wood

June 28, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

Advertisement

As More Peripheral Interventions Go Radial, the AHA Offers Some Insights

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

Top Endovascular News of 2023

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Impact on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: a meta-analysis of individual patient data from seven multicenter randomized clinical trials

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

MOSAIC: Home Intervention Boosts Walking Time in PAD Patients

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

PAD Continues to Elude Clinicians, Despite Gains: AHA

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

FDA’s First Take on New Paclitaxel Concerns in CLI

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

TCTMD’s Top 10 Most Popular Stories for June 2019

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content